Latest news with #AlphaIVFGroup
Yahoo
7 days ago
- Business
- Yahoo
Alpha IVF Group Berhad Full Year 2025 Earnings: Misses Expectations
Alpha IVF Group Berhad (KLSE:ALPHA) Full Year 2025 Results Key Financial Results Revenue: RM176.8m (up 5.5% from FY 2024). Net income: RM57.5m (up 8.5% from FY 2024). Profit margin: 33% (in line with FY 2024). EPS: RM0.012 (in line with FY 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Alpha IVF Group Berhad Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 13%. The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM157.2m (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM33.1m (67% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in Malaysia. Performance of the Malaysian Healthcare industry. The company's shares are up 5.5% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 2 warning signs for Alpha IVF Group Berhad (1 makes us a bit uncomfortable!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
7 days ago
- Business
- Yahoo
Alpha IVF Group Berhad Full Year 2025 Earnings: Misses Expectations
Alpha IVF Group Berhad (KLSE:ALPHA) Full Year 2025 Results Key Financial Results Revenue: RM176.8m (up 5.5% from FY 2024). Net income: RM57.5m (up 8.5% from FY 2024). Profit margin: 33% (in line with FY 2024). EPS: RM0.012 (in line with FY 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Alpha IVF Group Berhad Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 13%. The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM157.2m (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM33.1m (67% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in Malaysia. Performance of the Malaysian Healthcare industry. The company's shares are up 5.5% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 2 warning signs for Alpha IVF Group Berhad (1 makes us a bit uncomfortable!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Alpha IVF Group Berhad Full Year 2025 Earnings: Misses Expectations
Alpha IVF Group Berhad (KLSE:ALPHA) Full Year 2025 Results Key Financial Results Revenue: RM176.8m (up 5.5% from FY 2024). Net income: RM57.5m (up 8.5% from FY 2024). Profit margin: 33% (in line with FY 2024). EPS: RM0.012 (in line with FY 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Alpha IVF Group Berhad Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 13%. The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM157.2m (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM33.1m (67% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in Malaysia. Performance of the Malaysian Healthcare industry. The company's shares are up 5.5% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 2 warning signs for Alpha IVF Group Berhad (1 makes us a bit uncomfortable!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
